Trial Profile
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EMPA
- 01 Dec 2021 Post-hoc results published in the Diabetes, Obesity and Metabolism.
- 01 Aug 2021 Results of secondary analysis assessing the effect of empagliflozin on lipid profile and lipoprotein subfractions at baseline and after 3 months of treatment published in the Atherosclerosis
- 11 Feb 2019 Status changed from not yet recruiting to completed.